Michelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC’s ‘Closing Bell’ to discuss the criticism Novo has faced around high drug prices, the potential earnings impact if prices come down, and more.
You May Also Like
More From Author
Industrials have been showing we’re in a soft landing, says Strategas’ Chris Verrone
